Tag
The OCEANIC-STROKE randomized trial demonstrates that adding asundexian to antiplatelet therapy reduces ischemic stroke without a significant rise in major bleeding, though it increases lower gastrointestinal bleeding in patients with nonca
The STATICH trial assessed safety and efficacy of antiplatelet therapy after intracerebral hemorrhage, revealing increased hemorrhagic risk but fewer ischemic events among treated patients, highlighting ongoing clinical dilemmas.
This retrospective analysis reveals that standard antiplatelet therapy may reduce mortality compared to thrombolysis in acute spontaneous spinal cord infarction, highlighting the need for cautious therapeutic decisions pending stronger evid
A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.
This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.
A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resis
The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar
Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombo
This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinica
This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.
The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increa
The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.
This study found no overall advantage of anticoagulation over antiplatelet therapy in ESUS patients but identified a potential benefit of anticoagulation in those with left ventricular injury.
The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.
